Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 3/20 | 0.54 |
| ▸ | FYN | P06241 | 3/20 | 0.54 |
| ▸ | MINK1 | Q8N4C8 | 2/20 | 0.54 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.54 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.52 |
| ▸ | MTOR | P42345 | 3/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.51 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.51 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.51 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.48 |
| ▸ | GCK | P35557 | 1/20 | 0.47 |
| ▸ | GCKR | Q14397 | 1/20 | 0.47 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30565567 | 0.84 | KDM4E (0.64) | MAP4K4FYNMINK1TNIKPIK3CA | |
| SCHEMBL597932 | 0.84 | KDM4E (0.64) | MAP4K4FYNMINK1TNIKPIK3CA | |
| SCHEMBL13743136 | 0.83 | CA2 (0.61) | KDM4EMKNK1MKNK2PIK3CD | |
| SCHEMBL12077575 | 0.82 | GAA (0.52) | MAP4K4PIK3CAMTORKDM4EMKNK1 | |
| SCHEMBL2762071 | 0.82 | PIK3CG (0.54) | MAP4K4FYNMINK1TNIKPIK3CA | |
| SCHEMBL30337416 | 0.79 | PIK3CD (0.70) | MAP4K4MINK1TNIKKDM4EMKNK1 | |
| SCHEMBL27635242 | 0.79 | KCNH2 (0.48) | MAP4K4FYNMINK1TNIKPIK3CA | |
| SCHEMBL10157313 | 0.79 | MTOR (0.67) | MAP4K4FYNMINK1TNIKPIK3CA | |
| SCHEMBL387443 | 0.79 | ALOX5AP (0.52) | MAP4K4FYNMINK1TNIKKCNH2 | |
| SCHEMBL903914 | 0.78 | MAP4K4 (0.54) | MAP4K4FYNMINK1TNIKPIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102812006-B | Novel antimalaria reagent | MMV MEDICINES FOR MALARIA VENTURE (CH) | 2016-01-20 | — | — | CN | claimed |
| CN-102812006-B | Novel antimalaria reagent | MMV MEDICINES FOR MALARIA VENTURE (CH) | 2016-01-20 | — | — | CN | disclosed |
| US-8211913-B2 | 5-aryl pyridines as 11-beta inhibitors for the treatment of diabetes | HOFFMANN-LA ROCHE INC. (US) | 2012-07-03 | — | — | US | disclosed |
| US-20090149503-A1 | NEW 5-ARYL PYRIDINES AS 11-BETA INHIBITORS FOR THE TREATMENT OF DIABETES | AMREIN KURT | 2009-06-11 | — | — | US | disclosed |
| US-7528159-B2 | 5-aryl pyridines as 11-beta inhibitors for the treatment of diabetes | HOFFMANN-LA ROCHE INC. (US) | 2009-05-05 | — | — | US | disclosed |
| EP-1789041-B1 | ARYL-PYRIDINE DERIVATIVES AS 11-BETA-HSD1 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2008-07-09 | — | — | EP | disclosed |
| EP-1789041-A2 | ARYL-PYRIDINE DERIVATIVES AS 11-BETA-HSD1 INHIBITORS | F. Hoffmann-Roche AG (CH) | 2007-05-30 | — | — | EP | disclosed |
| US-20060025455-A1 | New 5-aryl pyridines as 11-beta inhibitors for the treatment of diabetes | HOFFMANN-LA ROCHE INC. | 2006-02-02 | — | — | US | disclosed |
| WO-2006010546-A2 | ARYL-PYRIDINE DERIVATIVES AS 11-BETA-HSD1 INHIBITORS | F. HOFFMAN-LA ROCHE AG (CH) | 2006-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149503-A1 | NEW 5-ARYL PYRIDINES AS 11-BETA INHIBITORS FOR THE TREATMENT OF DIABETES | GPR119, CYP4B1, SLC5A1 | MAP4K4 859/4885FYN 1714/4885MINK1 1051/4885 |
| US-20060025455-A1 | New 5-aryl pyridines as 11-beta inhibitors for the treatment of diabetes | GPR119, CYP4B1, SLC5A1 | MAP4K4 859/4885FYN 1714/4885MINK1 1051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.